Aisling Capital — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in
Board seatSteven ElmsAftab Kherani· per SEC Form D
Co-investorsARCH Venture PartnersOrbiMedCasdin CapitalFidelity InvestmentsGV (Google Ventures)Rock Springs Capital+1 more
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)Cherry Thomas(Executive Officer)Kumar Srinivasan(Executive Officer, Director)Keith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Co-investorsAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersAbingworthFidelity InvestmentsIntermediate Capital Group+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.